|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2011-12-20 |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床阶段不明 |
首次获批国家/地区- |
首次获批日期- |
|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A phase III double blind multicenter randomized prospective parallel group study to evaluate the efficacy and safety of test product fixed dose combination of Gabapentin 200 mg and Duloxetine 20 mg capsule and test product fixed dose combination of Gabapentin 300 mg and Duloxetine 30 mg capsule manufactured by Synokem Pharmaceuticals Limited New Delhi India when compared with the reference product fixed dose combination of Pregabalin 75 mg and Duloxetine 30 mg capsule in treatment of neuropathic pain - NIL
A Multi-centric, Open label, Randomized, Non-Comparative, Two-Arm, Phase IV clinical trial to evaluate the safety and efficacy of Imeglimin 500 mg and 1000 mg tablets in the treatment of patients diagnosed with type-II diabetes mellitus in adequate control of diet and exercise alone. - IME
A Multicentric, Randomized, Double Blind, Double Dummy, Active Controlled, Prospective, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Pregabalin, Duloxetine (As Gastro Resistant Pellets) and Mecobalamin Capsules Versus Fixed Dose Combination of Pregabalin, Nortriptyline and Mecobalamin Tablets for the Treatment of Patients with Diabetic Peripheral Neuropathic Pain with Coexistent Vitamin B12 Deficiency. - NIL
100 项与 Synokem Pharmaceuticals Ltd. 相关的临床结果
0 项与 Synokem Pharmaceuticals Ltd. 相关的专利(医药)
100 项与 Synokem Pharmaceuticals Ltd. 相关的药物交易
100 项与 Synokem Pharmaceuticals Ltd. 相关的转化医学